Skip to main content

Table 1 Patient demographics and baseline characteristics of patients ≥18 years of age in MOR-004/005 and MorCAP

From: Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa

 

ITT (n = 37)

MPP (n = 32)

MorCAP (n = 10)a

Demographics

 Age, mean (SD), yrs

30.9 (9.7)

30.3 (8.5)

26.9 (7.8)

 Male, n (%)

13 (35.1)

12 (37.5)

1 (10.0)

 Ethnicity, n (%)

  White

30 (81.1)

26 (81.3)

8 (80.0)

  Nonwhite

7 (18.9)

6 (18.8)

2 (20.0)

 Height, mean (SD), cm

114.1 (20.4)

114.6 (20.8)

106.4 (13.1)

Baseline characteristics, mean (SD)

 6MWT distance, m

176.9 (67.3)

175.3 (70.7)

148.6 (109.1)

 3MSCT, stairs/min

21.3 (13.1)

22.6 (13.2)

16.6 (15.3)

 uKS, μg/mg

9.5 (6.2)

9.6 (6.5)

7.2 (5.0)

 FVC, L

1.5 (1.1)

1.5 (1.1)

0.9 (0.3)

 FEV1, L

1.2 (0.8)

1.3 (0.9)

0.7 (0.3)

 MVV, L/min

43.2 (31.7)

44.9 (33.9)

29.8 (15.2)

 HAQ—self-care

2.7 (2.2)

2.0 (1.9)

2.4 (1.9)

 HAQ—caregiver assistance

23.0 (10.0)

23.7 (10.5)

25.8 (8.0)

 HAQ—mobility

5.4 (2.7)

5.5 (2.5)

5.4 (2.4)

  1. 3MSCT 3-min stair climb test, 6MWT 6-min walk test, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, HAQ Health Assessment Questionnaire, ITT intent to treat, MPP modified per-protocol, MVV maximal voluntary ventilation, uKS urinary keratan sulfate
  2. a n = 9 for 6MWT, 3MSCT, FVC, and FEV1; n = 7 for MVV; n = 4 for uKS. Includes only patients with data at year 2